In this issue:
- Impact of poverty and neighbourhood opportunity on young CAR T-cell recipients
- Big ICI response data identifies novel potential targets
- Perception of prognosis, QOL and distress in CAR T-cell recipients
- Pneumonitis risk in ICI-treated NSCLC with pre-existing ILD
- ICI effectiveness in advanced oesophageal squamous cell carcinoma
- ICI durability after cessation in metastatic Merkel cell carcinoma
- Pucotenlimab for locally advanced or metastatic melanoma
- Pembrolizumab vs. chemotherapy in nasopharyngeal cancer
- Outcome differences for ICIs according to infusion timing in advanced NSCLC
- Polyvalent vaccine + bevacizumab for recurrent ovarian cancer: long-term outcomes
Download PDF